British pharmaceuticals group AstraZeneca, which is finalizing a vaccine against Covid-19, said Saturday it was buying US biotech firm Alexion for $39 billion to boost its work on immunology. “Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases,” AstraZeneca chief executive Pascal Soriot said in a […]
Thank you for registering!
An account was already registered with this email. Please check your inbox for an authentication link.